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A B S T R A C T
Background: Who should be tested for viruses in patients with community acquired pneumonia (CAP), pre-
valence and risk factors for viral CAP are still debated. We evaluated the frequency of viral testing, virus pre-
valence, risk factors and treatment coverage with oseltamivir in patients admitted for CAP.
Methods: Secondary analysis of GLIMP, an international, multicenter, point-prevalence study of hospitalized
adults with CAP. Testing frequency, prevalence of viral CAP and treatment with oseltamivir were assessed
among patients who underwent a viral swab. Univariate and multivariate analysis was used to evaluate risk
factors.
Results: 553 (14.9%) patients with CAP underwent nasal swab. Viral CAP was diagnosed in 157 (28.4%) pa-
tients. Influenza virus was isolated in 80.9% of cases. Testing frequency and viral CAP prevalence were in-
homogeneous across the participating centers. Obesity (OR 1.59, 95%CI: 1.01–2.48; p=0.043) and need for
invasive mechanical ventilation (OR 1.62, 95%CI: 1.02–2.56; p=0.040) were independently associated with
viral CAP. Prevalence of empirical treatment with oseltamivir was 5.1%.
Conclusion: In an international scenario, testing frequency for viruses in CAP is very low. The most common
cause of viral CAP is Influenza virus. Obesity and need for invasive ventilation represent independent risk factors
for viral CAP. Adherence to recommendations for treatment with oseltamivir is poor.
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1. Introduction
Community acquired pneumonia (CAP) is the most frequent in-
fectious disease of the lower respiratory tract and represents a major
clinical burden worldwide, with World Health Organization estimates
reporting>450 million cases annually [1]. Furthermore, it represents
a substantial cost for healthcare systems (e.g.,> 10 billion dollars in
2011 in the United States [2]).
CAP can be caused by different micro-organisms, but recently
viruses have been identified as an important etiological pathogen in
CAP patients [2]. Incidence of viral CAP is high, with a major impact on
mortality worldwide [3], especially in developing countries [1].
Moreover, from 21% [2] to 28% [4] of hospitalized patients with viral
CAP require admission to the intensive care unit (ICU).
The prevalence of viruses as a cause of CAP might be under-
estimated in clinical practice because new molecular tests to identify
viral pathogens are not widely available in clinical practice [2]. Clinical
presentation of bacterial and viral pneumonia may overlap [5] and no
consensus exists on when and who should be tested and treated for viral
CAP [6]. Different reports have shown that its prevalence widely varies
from 8.6% to 56.2% [4–7], differing in terms of study design, diagnostic
techniques, and study populations. Notably, previous experiences were
mainly monocentric or limited to a few countries, and do not represent
data outside Europe and North America [4–7]. Importantly, viral CAP-
related risk factors differ from study to study [8–11]. Finally, current
available data shows that Influenza virus is the most prevalent cause of
viral CAP, for which oseltamivir is suggested as standard of care [6].
An evaluation of the global prevalence and risk factors associated
with viral CAP is necessary to help in the decision-making process.
The primary aim of the present study was to investigate the fre-
quency of testing for viruses and the prevalence of viral CAP at inter-
national level. The secondary aim was to describe the population of
patients with viral CAP and to evaluate oseltamivir use in a pragmatic
point prevalence study.
2. Methods
The present study is a secondary analysis of the database collected
for the GLIMP study, an international, multicenter, point-prevalence
study of hospitalized adult patients with a diagnosis of CAP [12]. De-
tailed methodology of the GLIMP study was published elsewhere [12].
The study was conducted in accordance with the amended Declaration
of Helsinki and was approved by the Institutional Review Board (IRB#
HSC20150184E) of The University of Texas Health Science Center at
San Antonio, TX, USA, and all participating centers were required to
comply with local, regional, or national research regulations to parti-
cipate in the study.
2.1. Inclusion and exclusion criteria
All adults (> 18 years old) hospitalized with CAP were screened for
study inclusion. The study sample included only patients who under-
went a viral nasopharyngeal or oropharyngeal swab during the first
24 h. Patients hospitalized with a diagnosis of hospital-acquired and/or
ventilator-associated pneumonia were excluded from the study [13].
2.2. Data collection
Study participants were enrolled on a single day in the months of
March, April, May, and June 2015. The following variables were col-
lected: age, height, weight, gender, job, smoking history, pharmacolo-
gical therapy, vaccination status, drug and alcohol abuse, oncological,
cardiovascular, respiratory, hepatic, and renal comorbidities, previous
healthcare exposure – i.e. emergency room admission, intravenous and
oral antibiotics, hospitalization, lower respiratory tract infections in the
previous 3, 6, and 12months - severity of disease in first 24 h of hospital
admission, prior infection or colonisation with multi-drug resistant
pathogens. For a detailed list of characteristics and risk factors eval-
uated please see the Appendix A. Patients' care workup might include
any of the following specimens: blood samples, acute-phase serum
specimens, urine samples, nasopharyngeal swabs, sputum in case of
productive cough, pleural fluid, endotracheal aspirates, and bronch-
oalveolar lavage samples. Only microbiological tests performed in the
first 24 h from admittance to the hospital were considered for the
analysis. All antimicrobial, antiviral, and antifungal treatments ad-
ministered within 24 h from the admission were recorded. Data were
collected and managed using an ad hoc report form and a dedicated
data capture tool [12].
2.3. Microbiological analysis
Patients' clinical management and collection of microbiological
samples depended on the attending physician, and not per study pro-
tocol. All microbiological examinations were performed according to
local standard protocols.
Upper airway specimens were obtained with nasopharyngeal or
oropharyngeal swabs for the detection of the following viruses:
Adenovirus, Coronavirus, human Metapneumovirus (HMPV), human
Rhinovirus, Influenza virus, and Respiratory Syncytial virus (RSV). Tests
for virus detection were carried out with polymerase chain reaction,
nucleic acid amplification tests (reverse transcriptase polymerase chain
reaction, RT-PCR), or rapid influenza diagnostic tests (RIDTs) according
to local standard protocols [14]. Classification of viral types and sub-
types was not performed. Based on the specificity and sensitivity of the
nasopharyngeal and oropharyngeal swabs [14], no other specimens
were considered valid for virus detection.
Microbiological testing for bacteria and fungi were performed ac-
cording to standard local protocols on any of the following: blood,
upper and lower tract respiratory cultures (e.g., sputum, pleural fluid,
endotracheal aspirate, and bronchoalveolar lavage), sputum gram stain,
urinary antigens for Streptococcus pneumoniae and Legionella pneumo-
phila and serology for Mycoplasma pneumoniae, Legionella pneumophila,
and Chlamydia pneumoniae.
2.4. Study definitions and groups
The detailed definition of CAP is reported in the Appendix A. A viral
CAP was defined as a pneumonia case in which at least one virus was
microbiologically detected in a respiratory sample. A mixed infection
was defined as a CAP in which a virus was detected together with either
bacteria or fungi. A coinfection, when present, was considered as a viral
CAP [15–18].
The study groups included in the analysis were the following:
a) The “tested for virus” group included patients who underwent at
least one nasopharyngeal or oropharyngeal swab and were com-
pared with patients not tested for viruses.
b) The “swab positive” group included patients of the “tested for virus”
group where a virus was microbiologically detected. It was com-
pared with patients tested for viruses and with a negative swab.
c) The “Influenza CAP” group included patients of the “swab positive”
group where Influenza virus was isolated; they were compared with
patients who performed a viral swab and were negative for Influenza
virus.
2.5. Statistical analysis
The frequency of viral nasopharyngeal swab tests was calculated
considering all the CAP patients included in the GLIMP dataset. The
prevalence of viral CAP was calculated using viral isolates detected
with viral nasopharyngeal swabs performed during the first 24 h of
hospital admission. Categorical variables, expressed as counts
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(percentages), were compared between groups using the Chi-squared or
Fisher test, when appropriate. Regressions analyses were performed to
compare prevalence and determine odds ratios (OR) with 95% con-
fidence interval (CI). Logistic regression analyses were performed to
assess the relationship between viral pneumonia, influenza virus
pneumonia and demographics, therapeutic, epidemiological, and clin-
ical variables. The Chi-squared test was performed to compare the
prevalence between countries and continents. Statistical significance
was defined as p-value< 0.05. All statistical analyses were performed
with IBM SPSS, Statistics for Windows, version 21.0 (Armonk, NY: IBM
Crop), and STATA 13 (College Station, TX: StataCorp LP).
3. Results
From 3702 CAP patients enrolled in the GLIMP study, 553 (14.9%)
were tested for viruses (median age: 66 years; 57.3% males), (Table A1
in the data Appendix A and Fig. 1). A total of 157 patients out of 553
(28.4%) had at least one isolated virus (“swab positive” group). Influ-
enza virus was isolated in 127/157 (80.9% of viral CAP) and formed the
“Influenza CAP” group (Fig. 1).
3.1. Frequency of viral testing
The frequency of nasal swab testing was significantly higher in Asia
(18.8%) and significantly lower in Africa (1.3%) (Table 1 and Fig. 2).
Spain, India, USA, and Italy were the countries with the highest viral
swab testing frequency once weighted for the number of patients en-
rolled (Figs. 2 and 3). Netherlands, and Saudi Arabia had the highest
testing frequency, whereas no viral swabs were performed in Portugal,
Croatia, Serbia, Montenegro, Bulgaria, Nigeria, and Romania (Fig. 2
and Table A2 in the Appendix A). Compared with those not tested for
viruses, tested patients were significantly younger and more obese, and
had more often a positive smoking history. The tested group had more
respiratory comorbidities, such as asthma and obstructive sleep apnea,
were more frequently transplanted and vaccinated with PPSV23, had
more frequently severe CAP at admission (Table 2).
3.2. Viral CAP prevalence and characteristics
In the swab positive group, 159 viruses were isolated, and the most
prevalent were Influenza virus (80.9%), RSV (5.7%), and Rhinovirus/
Enterovirus (5%) (Table 1). Two patients had two viruses isolated at the
same time, and, therefore, the total number of patients with viral CAP
was 157. Nineteen patients had a bacterial coinfection. The mostFig. 1. Flow chart describing the study samples.
Table 1
Frequency of viral testing, prevalence of viral community acquired pneumonia
and isolated viruses by continent.
Continent Within the
country
Other
continents
p-Value
North America
Viral swabs/all tests, n/N (%) 83/529 (15.6) 470/3173 (14.8) 0.600
Positive viral swabs, n/N (%) 15/83 (18.1) 142/470 (30.2) 0.024
Influenza virus, n (%) 8 (53.3) 119 (83.8) 0.002
Adenovirus, n (%) 0 (0.0) 3 (2.1) 1.000
Coronavirus, n (%) 1 (6.7) 5 (3.5) 0.127
RSV, n (%) 1 (6.7) 8 (5.6) 0.256
Metapneumovirus, n (%) 1 (6.7) 3 (2.1) 0.107
Rhinovirus/Enterovirus, n (%) 4 (26.7) 4 (2.8) <0.001
South America
Viral swabs performed, n/N (%) 25/218 (11.5) 528/3484 (15.2) 0.138
Positive viral swabs, n/N (%) 2/25 (8.0) 155/528 (29.4) 0.021
Influenza virus, n (%) 1 (50.0) 126 (81.3) 0.025
Adenovirus, n (%) 0 (0.0) 3 (1.9) 1.000
Coronavirus, n (%) 0 (0.0) 6 (3.9) 1.000
RSV, n (%) 1 (50.0) 8 (5.2) 0.084
Metapneumovirus, n (%) 0 (0.0) 4 (2.6) 1.000
Rhinovirus/Enterovirus, n (%) 0 (0.0) 8 (5.2) 1.000
Africa
Viral swabs performed, n/N (%) 2/156 (1.3) 551/3546 (15.5) <0.001
Positive viral swabs, n/N (%) 1/2 (50.0) 156/551 (28.3) 0.497
Influenza virus, n (%) 1 (100.0) 126 (80.8) 0.390
Adenovirus, n (%) 0 (0.0) 3 (1.9) 1.000
Coronavirus, n (%) 0 (0.0) 6 (3.8) 1.000
RSV, n (%) 0 (0.0) 9 (5.8) 1.000
Metapneumovirus, n (%) 0 (0.0) 4 (2.6) 1.000
Rhinovirus/Enterovirus, n (%) 0 (0.0) 8 (5.1) 1.000
Asia
Viral swabs performed, n/N (%) 78/415 (18.8) 475/3287 (14.5) 0.019
Positive viral swabs, n/N (%) 29/78 (37.2) 128/475 (26.9) 0.063
Influenza virus, n (%) 23 (79.3) 104 (81.3) 0.151
Adenovirus, n (%) 2 (6.9) 1 (0.8) 0.004
Coronavirus, n (%) 3 (10.3) 3 (2.3) <0.001
RSV, n (%) 1 (3.4) 8 (6.3) 0.242
Metapneumovirus, n (%) 0 (0.0) 4 (3.1) 1.000
Rhinovirus/Enterovirus, n (%) 0 (0.0) 8 (6.3) 1.000
Europe
Viral swabs performed, n/N (%) 361/2344 (15.4) 192/1358 (14.1) 0.299
Positive viral swabs, n/N (%) 108a/361 (29.9) 49/192 (25.5) 0.275
Influenza virus, n (%) 92 (85.2) 35 (71.4) 0.093
Adenovirus, n (%) 1a (0.9) 2 (4.1) 0.401
Coronavirus, n (%) 2 (1.9) 4 (8.2) 0.109
RSV, n (%) 6a (5.6) 3 (6.1) <0.001
Metapneumovirus, n (%) 3 (2.8) 1 (2.0) 0.008
Rhinovirus/Enterovirus, n (%) 4 (3.7) 4 (8.2) 0.008
Oceania
Viral swabs performed, n/N (%) 4/40 (10.0) 549/3662 (15.0) 0.378
Positive viral swabs, n/N (%) 2/4 (50.0) 155/549 (28.2) 0.320
Influenza virus, n (%) 2 (100.0) 125 (80.6) 0.210
Adenovirus, n (%) 0 (0.0) 3 (1.9) 1.000
Coronavirus, n (%) 0 (0.0) 6 (3.9) 1.000
RSV, n (%) 0 (0.0) 9 (5.8) 1.000
Metapneumovirus, n (%) 0 (0.0) 4 (2.6) 1.000
Rhinovirus/Enterovirus, n (%) 0 (0.0) 8 (5.2) 1.000
a In Europe 110 viruses were isolated in total. In 2 cases, 2 viruses were
isolated at the same time (Influenza virus+Adenovirus and Influenza
virus+RSV). In the latter cases, only the first reported virus was considered as
the cause of CAP, i.e. Influenza virus in both cases.
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frequent bacteria isolated in patients with Influenza CAP were Staphy-
lococcus aureus strains (21% of all coinfections) (Table A3 in the
Appendix A).
The overall prevalence of viral CAP was 28.4% of those tested.
North and South America had a significantly lower prevalence com-
pared with the other participating centers representing the continents,
whereas Asian countries had the highest prevalence. Compared with
other participating countries, North America had significantly lower
prevalence of Influenza virus and the highest prevalence of Rhinovirus/
Enterovirus (Table 1). Compared with all the other countries, India and
Italy had significantly higher prevalence of viral CAP, whereas USA and
Argentina had a significantly lower frequency (Table A2 in the
Appendix A).
Patients with viral CAP significantly differed from the rest of the
sample in terms of obesity, respiratory comorbidities, vaccination
status, and CAP severity (Table 2). Independent risk factors for viral
CAP were represented by obesity (OR 1.59, 95% CI: 1.01–2.48; p-
value= 0.043) and need for invasive mechanical ventilation on hos-
pital admission (OR 1.62, 95% CI: 1.02–2.56; p-value=0.040), (Table
A4 in the Appendix A).
Focusing the analysis only on patients with influenza, the only
significant risk factor associated with Influenza CAP was obesity. The
Influenza group significantly differed from the rest of the population
also in terms of inhaled corticosteroid use, vaccination status, and
hospitalization during the prior year to the admission (Table 2). No
independent risk factors for the occurrence of Influenza CAP were
found.
A total of 188 (5.1%) patients with CAP were empirically treated
with oseltamivir, 158 (28.6%) among all tested with nasal viral swabs,
and 93 (59.2%) among those with a viral CAP (Fig. 4). Among patients
Fig. 2. Frequency of testing for viruses as a percentage of all tests performed in each country and prevalence of viral CAP as a percentage of all the viral swabs
performed in each country. The size of each sphere indicates the number of patients with CAP enrolled in the GLIMP sample. Only countries with> 20 patients
enrolled are shown, excepted for United Arab Emirates, China and Austria that had a high frequency of testing despite the lower number of patients enrolled.
Fig. 3. Prevalence of influenza virus CAP (red area)
in relation to all cause viral CAP (blue area). The
ratio between swabs positive for influenza compared
to all positive swabs by each country is reported in
the left sided vertical axis. Absolute patients enrolled
in the study (grey area) are reported in the right
sided vertical axis. Only countries that have per-
formed at least one viral swab are shown. (For in-
terpretation of the references to colour in this figure
legend, the reader is referred to the web version of
this article.)
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Table 2
Characteristics and risk factors for being tested for viruses, have a viral CAP and have an Influenza virus CAP.
All CAP
N = 3702
Variables Other tests
N = 3149
Viral
swabs
N = 553
P-value All viral swabs
N = 553
Swab
positive
N = 157
Swab
negative
N = 396
p-value Influenza
positive
N = 127
Influenza
negative
N = 427
p-value
Age, median (IQR) years 69.0 (54-
80)
66.0 (51-
77)
<0.001 62.0 (47-75) 67.0 (52-78) 0.083 63.0 (48-77) 67.0 (52-78) 0.160
Male, n (%) 1,826 (58.0) 317 (57.3) 0.771 97 (61.8) 220 (55.6) 0.180 79 (62.2) 238 (55.9) 0.205
Underweight, n (%) 141/1987
(7.1)
25/342
(7.3)
0.887 3/103 (2.9) 22/239 (9.2) 0.040 3/92 (3.3) 22/250 (8.8) 0.081
Obesity, n (%) 459 (14.6) 118 (21.3) <0.001 44 (28.0) 74 (18.7) 0.016 36 (28.3) 82 (19.2) 0.028
Active lung cancer, n (%) 99 (3.1) 10 (1.8) 0.087 5 (3.2) 5 (1.3) 0.156 4 (3.1) 6 (1.4) 0.196
Asthma, n (%) 210 (6.7) 51 (9.2) 0.030 12 (7.6) 39 (9.8) 0.419 10 (7.9) 41 (9.6) 0.550
Bronchiectasis, n (%) 150 (4.8) 28 (5.1) 0.761 3 (1.9) 25 (6.3) 0.032 3 (2.4) 25 (5.9) 0.114
Chronic aspiration, n (%) 230 (7.3) 43 (7.8) 0.039 6 (3.8) 21 (5.3) 0.466 4 (3.1) 23 (5.4) 0.302
COPD, n (%) 795 (25.2) 27 (4.9) 0.900 40 (25.5) 101 (25.5) 0.995 32 (25.2) 109 (25.6) 0.929
FEV1 ≤30%, n (%) 84 (2.7) 141 (25.5) 0.763 5 (3.2) 11 (2.8) 0.782 5 (3.9) 11 (2.6) 0.424
Current/former smoker, n (%) 1,011 (32.1) 234 (42.3) <0.001 72 (45.9) 162 (40.9) 0.288 58 (45.7) 176 (41.3) 0.383
Interstitial lung disease, n (%) 75 (2.4) 20 (3.6) 0.090 0 (0.0) 20 (5.1) 0.002 0 (0.0) 20 (4.7) 0.013
Obstructive sleep apnoea, n (%) 96 (3.0) 34(6.1) <0.001 8 (5.1) 26 (6.6) 0.516 7 (5.5) 27 (6.3) 0.734
Long term oxygen therapy (LTOT), n (%) 186 (5.9) 38 (6.9) 0.380 5 (3.2) 33 (8.3) 0.039 4 (3.1) 34 (8.0) 0.059
Lung transplantation, n (%) 2 (0.1) 5 (0.9) <0.001 0 (0.0) 5 (1.3) 0.328 0 (0.0) 5 (1.2) 0.220
Tracheostomy, n (%) 44 (1.4) 9 (1.6) 0.674 0 (0.0) 9 (2.3) 0.067 0 (0.0) 9 (2.1) 0.099
Arrhythmia, n (%) 454 (14.4) 73 (13.2) 0.450 18 (11.5) 55 (13.9) 0.448 12 (9.4) 61 (14.3) 0,155
Coronary artery disease, n (%) 520 (16.5) 66 (11.9) 0.127 17 (10.8) 60 (15.2) 0.185 11 (8.7) 66 (15.5) 0.051
Heart failure, n (%) 423 (13.4) 62 (11.2) 0.153 11 (7.0) 51 (12.9) 0.048 9 (7.1) 53 (12.4) 0.093
Hypertension, n (%) 1,417 (45.0) 238 (43.0) 0.392 64 (40.8) 174 (43.9) 0.497 49 (38.6) 189 (44.4) 0.248
Stroke, n (%) 267 (8.5) 39 (7.1) 0.261 8 (5.1) 31 (7.8) 0.258 5 (3.9) 34 (8.0) 0.118
Inhaled corticosteroids use, n (%) 492 (15.6) 98 (17.7) 0.214 18 (11.5) 80 (20.2) 0.015 12 (9.4) 86 (20.2) 0.005
Proton Pump Inhibitor use, n (%) 851 (27.0) 177 (32.0) 0.016 48 (30.6) 129 (32.6) 0.649 35 (27.6) 142 (33.3) 0.221
Statins use, n (%) 612 (19.4) 143 (25.9) 0.001 40 (25.5) 103 (26.0) 0.897 28 (22.0) 115 (27.0) 0.264
Steroids use, n (%) 239 (7.6) 55 (9.9) 0.059 17 (10.8) 38 (9.6) 0.662 10 (7.9) 45 (10.6) 0.374
Enteric tube feeding, n (%) 41 (1.3) 11 (2.0) 0.205 0 (0.0) 11 (2.8) 0.039 0 (0.0) 11 (2.6) 0.067
Haemodialysis, n (%) 43 (1.4) 9 (1.6) 0.629 3 (1.9) 6 (1.5) 0.718 2 (1.6) 7 (1.6) 0.957
Indwelling catheter, n (%) 72 (2.3) 7 (1.3) 0.126 1 (0.6) 6 (1.5) 0.679 0 (0.0) 7 (1.6) 0.146
Active solid tumour, n (%) 250 (7.9) 37 (6.7) 0.311 15 (9.6) 22 (5.6) 0.090 11 (8.7) 26 (6.1) 0.311
AIDS, n (%) 56 (1.8) 9 (1.6) 0.803 1 (0.6) 8 (2.0) 0.457 1 (0.8) 8 (1.9) 0.394
Aplastic anaemia, n (%) 13 (0.4) 1 (0.2) 0.412 1 (0.6) 0 (0.0) 0.284 1 (0.8) 0 (0.0) 0.067
Asplenia, n (%) 9 (0.3) 3 (0.5) 0.327 2 (1.3) 1 (0.3) 0.196 1 (0.8) 2 (0.5) 0.669
Biological drug use, n (%) 28 (0.9) 9 (1.6) 0.107 3 (1.9) 6 (1.5) 0.718 2 (1.6) 7 (1.6) 0.957
Chemotherapy in the last 3months, n (%) 115 (3.7) 30 (5.4) 0.047 13 (8.3) 17 (4.3) 0.062 9 (7.1) 21 (4.9) 0.346
Haematological malignancy, n (%) 118 (3.7) 44 (8.0) <0.001 13 (8.3) 31 (7.8) 0.859 9 (7.1) 35 (8.2) 0.680
HIV infection, n (%) 105 (3.3) 18 (3.3) 0.923 3 (1.9) 15 (3.8) 0.425 3 (2.4) 15 (3.5) 0.518
Immunocompromised patients, n (%) 546 (17.3) 119 (21.5) 0.018 35 (22.3) 84 (21.2) 0.780 24 (18.9) 95 (23.3) 0.413
Neutropenia, n (%) 38 (1.2) 10 (1.8) 0.249 2 (1.3) 8 (2.0) 0.732 2 (1.6) 8 (1.9) 0.822
Other immunosuppressive condition, n (%) 108 (3.4) 34 (6.1) 0.002 4 (2.5) 30 (7.6) 0.030 2 (1.6) 32 (7.5) 0.015
Chronic renal failure, n (%) 343 (10.9) 57 (10.3) 0.683 16 (10.2) 41 (10.4) 0.955 13 (10.2) 44 (10.3) 0.976
Dementia, n (%) 369 (11.7) 39 (7.1) 0.001 8 (5.1) 31 (7.8) 0.258 8 (6.3) 31 (7.3) 0.706
Diabetes mellitus, n (%) 658 (20.9) 124 (22.4) 0.417 35 (22.3) 89 (22.5) 0.963 27 (21.3) 97 (22.8) 0.720
Liver disease, n (%) 115 (3.7) 25 (4.5) 0.323 5 (3.2) 20 (5.1) 0.496 5 (3.9) 20 (4.7) 0.718
Cirrhosis, n (%) 57 (1.8) 13 (2.4) 0.389 5 (3.2) 8 (2.0) 0.533 5 (3.9) 8 (1.9) 0.179
Malnutrition, n (%) 270 (8.6) 53 (9.6) 0.438 5 (3.2) 48 (12.1) 0.001 5 (3.9) 48 (11.3) 0.014
Alcoholism 242 (7.7) 52 (9.4) 0.168 14 (8.9) 38 (9.6) 0.805 12 (9.4) 40 (9.4) 0.984
Mental illness, n (%) 222 (7.0) 32 (5.8) 0.278 13 (8.3) 19 (4.8) 0.114 11 (8.7) 21 (4.9) 0.114
Prosthetic material, n (%) 98 (3.1) 18 (3.3) 0.859 3 (1.9) 15 (3.8) 0.425 3 (2.4) 15 (3.5) 0.518
Recurrent skin infections, n (%) 49 (1.6) 9 (1.6) 0.901 0 (0.0) 9 (2.3) 0.067 0 (0.0) 9 (2.1) 0.099
Bedridden, n (%) 376 (11.9) 39 (7.1) 0.001 9 (5.7) 30 (7.6) 0.445 7 (5.5) 32 (7.5) 0.440
Contact sport, n (%) 6 (0.2) 0 (0.0) 0.304 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Healthcare worker, n (%) 38 (1.2) 9 (1.6) 0.415 2 (1.3) 7 (1.8) 1.000 0 (0.0) 9 (2.1) 0.099
Homeless, n (%) 31 (1.0) 4 (0.7) 0.558 0 (0.0) 4 (1.0) 0.582 0 (0.0) 4 (0.9) 0.273
Injection of illicit drugs, n (%) 30 (1.0) 12 (2.2) 0.013 2 (1.3) 10 (2.5) 0.524 1 (0.8) 11 (2.6) 0.223
Living in crowded conditions, n (%) 628 (19.9) 93 (16.8) 0.087 23 (14.6) 70 (17.7) 0.391 20 (15.7) 73 (17.1) 0.714
Nursing home resident, n (%) 261 (8.3) 41 (7.4) 0.488 7 (4.5) 34 (8.6) 0.095 6 (4.7) 35 (8.2) 0.187
Worker in livestock meat industry, n (%) 29 (0.9) 2 (0.4) 0.183 0 (0.0) 2 (0.5) 1.000 0 (0.0) 2 (0.5) 0.439
Prior mycobacterial diseases, n (%) 85 (2.7) 11 (2.0) 0.333 2 (1.3) 9 (2.3) 0.448 2 (1.6) 9 (2.1) 0.703
Prior MRSA infection/colonisation, n (%) 69 (2.2) 17 (3.1) 0.204 3 (1.9) 14 (3.5) 0.419 2 (1.6) 15 (3.5) 0.265
Prior ESBL-producing bacterial infection, n (%) 46 (1.5) 9 (1.6) 0.765 2 (1.3) 7 (1.8) 1.000 1 (0.8) 8 (1.9) 0.394
Prior Pseudomonas spp. infection, n (%) 94 (3.0) 7 (1.3) 0.022 0 (0.0) 7 (1.8) 0.200 0 (0.0) 7(1.6) 0.146
Antibiotic infusion at home in the last 12
months, n (%)
141 (4.5) 13 (2.4) 0.471 3 (1.9) 18 (4.5) 0.216 2 (1.6) 19 (4.5) 0.135
(continued on next page)
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with a severe CAP at presentation (N=1030, 27.8%), 105 (10.2%)
patients were started on oseltamivir, while 83 (3.1%) patients without a
severe CAP received empirical oseltamivir (p-value<0.001). Differ-
ences in frequency of oseltamivir treatment among continents and
countries are reported in Table A5.
4. Discussion
This secondary analysis of an international, multicenter, point-pre-
valence study showed that patients with CAP had a low rate of viral
testing, low prevalence of viral pathogens, and a geographical hetero-
geneity regarding the viral assessment. Immunocompromised state,
prior respiratory comorbidities, and clinical severity of CAP were the
variables more frequently associated with viral testing. Obesity and
need for invasive mechanical ventilation were the only risk factors in-
dependently associated with the diagnosis of viral CAP. Furthermore,
only one third of CAP patients with suspected viral infection who un-
derwent viral testing were empirically treated with oseltamivir for in-
fluenza coverage.
Viral CAP is a relevant cause of morbidity and mortality worldwide
and its prevalence is likely underestimated due to low rates of and in-
consistent testing for viruses in general practice [19]. Presently, there
are no specific guidelines available for when to test for viruses in hos-
pitalized patients with CAP [6]. However, early diagnosis and treat-
ment of viral CAP caused by Influenza virus is known to have notable
clinical implications [20]. In this regard, several studies showed that
prevalence of viral CAP varies from 15% to 35% [2,7,9,10,21–23];
however, these studies limit data analyses to only tested patients or all
the patients enrolled were systematically tested for viral infection
[2,7,9,10,21–23]. In the present study, which was an attempt to assess
real-life scenarios,< 15% of patients were tested for viruses with a
prevalence of viral CAP of 28.4% among those tested, consistent with
the recent results of a systematic review [7]. In line with previous re-
ports [7,24,25], our results showed that Influenza virus was the most
prevalent pathogen isolated, accounting for 80.9% of positive swabs,
and this was consistent with the majority of the participating countries.
Nevertheless, a remarkable difference in testing frequency occurred
between the Northern and the Southern hemisphere. In fact, although
the study period included the influenza season in both boreal and
austral areas, Spain, India, USA, and Italy were the countries with the
Table 2 (continued)
All CAP
N = 3702
Variables Other tests
N = 3149
Viral
swabs
N = 553
P-value All viral swabs
N = 553
Swab
positive
N = 157
Swab
negative
N = 396
p-value Influenza
positive
N = 127
Influenza
negative
N = 427
p-value
Emergency room admission in the last 12
months, n (%)
993 (29.6) 91 (16.5) 0.721 41 (26.1) 127 (32.1) 0.170 34 (26.8) 134 (31.5) 0.314
Hospitalisation in the last 12 months, n (%) 992 (31.5) 108 (19.5) 0.786 36 (22.9) 135 (34.1) 0.010 28 (22.0) 143 (33.6) 0.014
IV antibiotics in the last 12 months, n (%) 771 (24.5) 90 (16.3) 0.899 30 (19.1) 104 (26.3) 0.077 25 (19.7) 109 (25.6) 0.173
LRTI in the last 12months, n (%) 891 (28.3) 103 (18.6) 0.572 35 (22.3) 115 (29.0) 0.108 33 (26.0) 117 (27.5) 0.742
Oral antibiotics in the last 12 months, n (%) 1,207 (38.3) 115 (20.8) 0.029 55 (35.0) 130 (32.8) 0.620 45 (35.4) 140 (32.9) 0.590
Influenza vaccine 868 (27.6) 153 (27.7) 0.960 30 (19.1) 123 (31.1) 0.005 23 (18.1) 130 (30.5) 0.006
PCV13 115 (3.7) 12 (2.2) 0.077 2 (1.3) 10 (2.5) 0.524 1 (0.8) 11 (2.6) 0.223
PPSV23 331 (10.5) 76 (13.7) 0.025 12 (7.6) 64 (16.2) 0.009 9 (7.1) 67 (15.7) 0.013
Severe CAP, n (%) 811 (25.8) 219 (39.6) <0.001 73 (46.5) 146 (36.9) 0.037 57 (44.9) 162 (38.0) 0.166
Invasive mechanical ventilation 243 (7.7) 111 (20.1) <0.001 43 (27.4) 68 (17.2) 0.007 33 (26.0) 78 (18.3) 0.058
Non-invasive mechanical ventilation 272 (8.6) 77 (13.9) <0.001 28 (17.8) 49 (12.4) 0.094 20 (15.7) 57 (13.4) 0.499
CAD=Coronary artery disease; CAP=Community-acquired pneumonia; COPD= chronic obstructive pulmonary disease; ESBL= extended-spectrum beta-lacta-
mases; FEV1= Forced expiratory volume in one second; HIV=Human Immunodeficiency virus; LRTI= lower respiratory tract infection; LTOT= long term oxygen
therapy; MRSA=methicillin resistant Staphylococcus aureus; PCV13=pneumococcal conjugate vaccine; PPSV23=pneumococcal polysaccharide vaccine.
Fig. 4. Prevalence of empiric treatment with oseltamivir
among patients tested with a viral swab. Blue areas represent
negative swabs, while grey areas represent swabs positive for
either Influenza virus (light grey) or all other viruses (dark
grey). For every area, the striped part indicates the percentage
of patients empirically covered with oseltamivir.
Pos= positive; neg=negative. (For interpretation of the re-
ferences to colour in this figure legend, the reader is referred
to the web version of this article.)
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highest viral swab testing frequency once weighted for the number of
patients enrolled. We can speculate that this finding is most likely re-
lated to the epidemiology of Influenza and to differences in local
standard procedures.
Several factors are inconsistently considered by clinicians to make
decisions regarding when to test for viral pathogens. Literature shows
that patients are more likely to be tested based on severity of pre-
sentation [26], advanced age [10], presence of specific symptoms or
findings on imaging studies [9], and presence of inflammatory markers
[27,28]. However, patient's signs and symptoms, are not specific for
viral infections, overlapping with bacterial CAP [9,29]. Our observa-
tions may be supported by previous experience during the influenza
H1N1 pandemic, showing a higher prevalence and more severe pre-
sentation in younger and obese patients compared with non-severely
obese patients [30,31]. This evidence may have influenced current
clinical practice raising clinical suspicion on patients with these char-
acteristics. Furthermore, previous large studies adopted restrictive se-
lection criteria, excluding immunocompromised patients [2], transplant
recipients, or patients with previous tuberculosis [9] so may lack ap-
plication to real life clinical circumstances. In the current study, we
found that patients were more likely to undergo testing for viruses if
they had more severe CAP, had prior respiratory comorbidities, were
obese, or were immunocompromised due to malignancy, transplant
history, or previous chemotherapy. Our group recently studied the
etiology of CAP in immunocompromised patients and found that the
prevalence of Influenza virus was similar in immunocompromised and
immunocompetent patients [32]. Based on this epidemiological back-
ground, immunocompromised patients with CAP should be tested for
other viruses, avoiding the underestimation of the risk of other patho-
gens.
We found that obesity and need for invasive mechanical ventilation
were the only two risk factors associated with increased incidence of
viral CAP; however, obesity was the only independent risk factor as-
sociated with influenza CAP. This is consistent with findings of animal
models which suggested a role of leptin dysregulation in more severe
disease [33,34], while a higher incidence and severity of viral CAP was
found in obese patients [30,31,35,36]; on the other hand, several stu-
dies showed that severity of CAP and need for ICU admittance with
invasive ventilation were not associated with etiology
[10,17,21,37–39]. Thus, we conclude that obesity is the only in-
dependent risk factor predisposing patients to influenza infection, al-
though the association of obesity and viral CAP, and then, with influ-
enza CAP, could be over-represented by the large proportion of patients
with Influenza virus diagnosed in this cohort.
The ATS/IDSA guidelines strongly recommend early treatment with
oseltamivir in patients with influenza [6]. A systematic review carried
out in 2014 reported inconclusive data on the efficacy of influenza
therapy [40], but several prospective and retrospective studies showed
that treatment with oseltamivir reduced median time to symptoms'
recovery and incidence of complications associated with influenza
[41,42], as well as improved outcomes in patients requiring admittance
to ICU [43]. Furthermore, a recent systematic review showed that early
administration of neuraminidase inhibitors, such as oseltamivir, re-
duced mortality and pneumonia, as well as secondary transmission
[44]. The present study showed that only 5.1% of patients admitted
with CAP were empirically treated within 24 h and only half of patients
with confirmed influenza infection were started on therapy with osel-
tamivir or another neuraminidase inhibitor. Moreover, severity of CAP
at admittance appeared to represent a reason to start empirical cov-
erage with oseltamivir.
Oseltamivir, which should be administered in the first 48–72 h from
symptoms occurrence, seems to be the most preferred treatment for
influenza despite its costs [45]. An increase in influenza vaccination
coverage could reduce the burden of the disease and the prescription-
related costs.
Viral CAP was recently demonstrated to be a major cause of
pneumonia in critically ill patients requiring mechanical ventilation
[46], and our data confirm the need for systematic viral testing in all
patient admitted with CAP. Vast global heterogeneity in treatment and
low treatment rates can be explained by the lack of specific treatment
protocols at many institutions and poor adherence to recommendations.
The present study has several limitations. Firstly, based on the study
design across multiple institutions, investigators did have different
policies for viral testing. If centers were selectively using kits only for
influenza, our findings could be biased underestimating the role played
by other viruses. Moreover, only upper airway specimens were tested
for viruses, decreasing the diagnostic yield. Many countries had no
patients tested for viruses, and in the majority of the cases this was
associated with the missing prescription of oseltamivir. This disparity
could be influenced by several factors, including: 1) lack of or in-
adequate standard operating procedures and local guidelines for viral
testing, 2) poor healthcare resources, or 3) delay of referral to the
hospital from symptoms initiation, making the oseltamivir administra-
tion ineffective. The study period may also have influenced the pre-
valence of viral testing, especially for influenza in the northern hemi-
sphere. Furthermore, the present study did not evaluate outcomes of
patients treated with oseltamivir in comparison with those who did not
receive therapy. Finally, viral identification was assessed by local pro-
tocol and not per study guidelines. In fact, compared with other par-
ticipating centers, North America had the highest prevalence of
Rhinovirus/Enterovirus pneumonia. This is line with data from the
EPIC study [2], although it may be explained by different PCR sensi-
tivity which increased the diagnostic yield for those specific pathogens
[47]. We acknowledge that the pragmatic approach of the study re-
presents an important limitation: microbiological sampling and pa-
tients' management depend on local standard procedures and not by a
study protocol. However, the results of the present study show the
everyday clinical practice in different real-life settings, thus, integrating
data from randomized clinical trials and describing weaknesses and
strengths of the current management of CAP patients.
In conclusion, on an international scale the frequency of testing for
viral infections in patients admitted for CAP is very low and there is
significant variability between countries. Globally, the most common
cause of viral CAP is Influenza virus, with high geographical hetero-
geneity, and obese patients were more likely to undergo testing. It will
be important to develop specific guidelines and protocols on testing
patients for viruses to avoid leaving this decision to the clinician's
preference. Finally, empiric treatment with oseltamivir was low and
only half of patients with confirmed influenza infection received
treatment with oseltamivir. Further evaluation on viral testing other
than influenza virus is needed, based on the poor usefulness in the
clinical management.
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Appendix A
A.1. Risk factors and patients' characteristics
For every patient, the following characteristics and risk factors were included in the report form:
a) Anthropometric variables: age, gender, height and weight (from which the variables obesity and underweight were calculated).
b) Respiratory tract comorbidities included the presence of: active lung cancer, asthma, bronchiectasis, chronic aspiration, chronic obstructive
pulmonary disease (COPD), forced expiratory volume in one second (FEV1) ≤30%predicted value according to gender, age and ethnicity, smoke
history (current/former smoker), interstitial lung disease, obstructive sleep apnea, long term oxygen therapy, lung transplantation, tracheostomy.
c) Cardiovascular comorbidities included the presence of: arrhythmia, coronary artery disease, heart failure, arterial hypertension, stroke.
d) Pharmacological therapy included the chronic treatment with: inhaled corticosteroids, proton pump inhibitors, statins use, steroids use,
e) Presence of prosthetic materials: enteric tube feeding, haemodialysis, indwelling catheter
f) Presence of immunodepressive conditions within 6months of hospital admission: active solid tumour, acquired immune deficiency syndrome,
aplastic anaemia, asplenia, biological drug use, chemotherapy in the last 3months, hematological malignancy, HIV infection, neutropenia,
g) Presence of other comorbidities and risk factors: chronic renal failure, dementia, diabetes mellitus, liver disease, cirrhosis, malnutrition, alco-
holism, mental illness, prosthetic material, recurrent skin infections, bedridden, contact sport, healthcare worker, homeless, injection of illicit
drugs, living in crowded conditions, nursing home resident, worker in livestock meat industry, prior mycobacterial diseases,
h) Known infection or colonisation within 12months of hospital admission with any of the following: methicillin resistant Staphylococcus aureus
(MRSA), Pseudomonas aeruginosa or extended spectrum beta-lactamase producing gram-negative bacilli (ESBL).
i) Previous healthcare exposure including: Antibiotic infusion at home in the last 3,6 and 12months, emergency room admission in the last 3, 6 and
12months, hospitalization in the last 3, 6 and 12months, intravenous antibiotics in the last 3, 6 and 12months, lower respiratory tract infections
(LRTI) in the last 3, 6 and 12months, oral antibiotics in the last 3,6 and 12months,
j) Vaccine status: influenza vaccine in the current or past influenza season, pneumococcal conjugate vaccine (PCV), pneumococcal polysaccharide
vaccine (PPSV23),
k) Need for the following within 24 h after hospital admission: invasive and/or non-invasive mechanical ventilation, intensive care unit (ICU) or
high dependency unit/semi-intensive care unit admittance, vasopressors, inotropes.
A.2. Study definitions
A.2.1. CAP
Community-acquired pneumonia (CAP) was defined by evidence of new pulmonary infiltrates on thoracic imaging (chest radiograph, computed
tomography scan, or ultrasound) during the first 48 h in hospital and at least one of the following criteria: new or increased cough with or without
sputum production or with purulent respiratory secretions; fever (documented rectal or oral temperature≥ 37·8 °C) or hypothermia (documented
rectal or oral temperature < 36 °C); and evidence of systemic inflammation, such as abnormal white blood cell count (leukocytosis [> 10,000 cells
per mL], leucopenia [< 4000 cells per mL], or bandaemia [> 10%]) and increased C-reactive protein or procalcitonin concentrations above the
local upper limit of normal.
A.2.2. Severe CAP
Severe CAP was defined by patients requiring any of the following: ICU admission, invasive or non-invasive mechanical ventilation, vaso-
pressors/inotropes during the first 24 h of hospital admission.
A.2.3. Severe COPD
Severe COPD was defined having either a FEV1 < 30%predicted value or being on long term oxygen therapy.
A.2.4. Vaccination
Influenza vaccination was considered valid if done during the prior and/or current influenza season. Previous pneumococcal vaccination in-
cluded conjugate - i.e. PCV7, PCV10 or PCV13 – or PPSV23.
A.2.5. Immunodepression
Immunodepression was defined as the presence during at least six months prior to hospital admission of any of the following: hematological
malignancy, asplenia, aplastic anaemia, neutropenia, chronic biological drugs use, chronic steroid treatment, HIV/AIDS and chemotherapy.
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A.2.6. Other immunosuppressive conditions
Any immunosuppressive state including congenital/genetic immunosuppression and immunosuppressive therapy due to hematological/solid
organ transplantation other than lung (excluding hematological malignancies, asplenia, aplastic anaemia, neutropenia, chronic biological drugs,
chronic steroid treatment, HIV/AIDS and chemotherapy) during.
At least six months before hospital admission.
Table A1
Anthropometric and clinical characteristics of patients that were tested with viral swabs.
Variables Patients tested for viral Swab N=553
Demographic characteristics
Age, median (IQR) years (47–77)
Male, n (%) 317 (57.3)
Underweight, n (%) 25/342 (7.3)
Obesity, n (%) 118 (21.3)
Respiratory past medical history
Active lung cancer, n (%) 10 (1.8)
Asthma, n (%) 51 (9.2)
Bronchiectasis, n (%) 28 (5.1)
Severe COPD, either FEV1 < 30% or LTOT, n (%) 43 (7.8)
COPD, n (%) 141 (25.5)
FEV1≤30%, n (%) 16(2.9)
Chronic aspiration, n (%) 27 (4.9)
Current/former smoker, n (%) 234 (42.3)
Interstitial lung disease, n (%) 20 (3.6)
Obstructive sleep apnea, n (%) 34(6.1)
Oxygen therapy at home (LTOT), n (%) 38 (6.9)
Lung transplantation, n (%) 5 (0.9)
Tracheostomy, n (%) 9 (1.6)
Cardiovascular past medical history
Arrhythmia, n (%) 73 (13.2)
Coronary artery disease, n (%) 66 (11.9)
Acute myocardial infarction, n (%) 39 (7.1)
Coronary artery disease with AMI, n (%) 77 (13.9)
Heart failure, n (%) 62 (11.2)
Hypertension, n (%) 238 (43.0)
Stroke, n (%) 39 (7.1)
Chronic medications
Inhaled corticosteroids use, n (%) 98 (17.7)
Proton Pump Inhibitor use, n (%) 177 (32.0)
Statins use, n (%) 143 (25.9)
Steroids use, n (%) 55 (9.9)
Chronic interventions
Enteric tube feeding, n (%) 11 (2.0)
Haemodialysis, n (%) 9 (1.6)
Indwelling catheter, n (%) 7 (1.3)
Immunosuppressive conditions
Active solid tumour, n (%) 37 (6.7)
AIDS, n (%) 9 (1.6)
Aplastic anaemia, n (%) 1 (0.2)
Asplenia, n (%) 3 (0.5)
Biological drug use, n (%) 9 (1.6)
Chemotherapy in the last 3months, n (%) 30 (5.4)
Hematological malignancy, n (%) 44 (8.0)
HIV infection, n (%) 18 (3.3)
Immunocompromised patients, n (%) 119 (21.5)
Neutropenia, n (%) 10 (1.8)
Other immunosuppressive condition, n (%) 34 (6.1)
Other chronic medical conditions
Chronic renal failure, n (%) 57 (10.3)
Dementia, n (%) 39 (7.1)
Diabetes mellitus, n (%) 124 (22.4)
Liver disease, n (%) 25 (4.5)
Cirrhosis, n (%) 13 (2.4)
Malnutrition, n (%) 53 (9.6)
Alcoholism 52 (9.4)
Mental illness, n (%) 32 (5.8)
Prosthetic material, n (%) 18 (3.3)
Recurrent skin infections, n (%) 9 (1.6)
Other non-medical conditions
Bedridden, n (%) 39 (7.1)
Contact sport, n (%) 0 (0.0)
Healthcare worker, n (%) 9 (1.6)
(continued on next page)
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Table A1 (continued)
Variables Patients tested for viral Swab N=553
Homeless, n (%) 4 (0.7)
Injection of illicit drugs, n (%) 12 (2.2)
Living in crowded conditions, n (%) 93 (16.8)
Nursing home resident, n (%) 41 (7.4)
Worker in livestock meat industry, n (%) 2 (0.4)
Previous infections/colonisation
Prior mycobacterial diseases, n (%) 11 (2.0)
Prior MRSA infection/colonisation, n (%) 17 (3.1)
Prior ESBL-producing bacterial infection, n (%) 9 (1.6)
Prior Pseudomonas spp. infection, n (%) 7 (1.3)
Prior healthcare exposure
Antibiotic infusion at home in the last 12months, n (%) 13 (2.4)
Emergency room admission in the last 12months, n (%) 91 (16.5)
Hospitalization in the last 12months, n (%) 108 (19.5)
IV antibiotics in the last 12months, n (%) 90 (16.3)
LRTI in the last 12months, n (%) 103 (18.6)
Oral antibiotics in the last 12months, n (%) 115 (20.8)
Influenza vaccine 153 (27.7)
PSV13 12 (2.2)
PPV23 76 (13.7)
Current pneumonia episode
Severe CAP, n (%) 219 (39.6)
Inotropes 11 (2.0)
Vasopressor 88 (15.9)
Invasive mechanical ventilation 111 (20.1)
Non-invasive mechanical ventilation 77 (13.9)
Either ICU or HDU, n (%) 195 (35.3)
ICU admission, n (%) 163 (29.5)
HDU admission, n (%) 36 (6.5)
CAP= community-acquired pneumonia; MRSA=methicillin resistant Staphylococcus aureus; COPD= chronic obstructive pulmonary disease; FEV1= forced ex-
piratory volume in one second; CAD= coronary artery disease; ESBL= extended-spectrum beta-lactamases; LRTI= lower respiratory tract infection.
Table A2
Frequency of viral swab testing and prevalence of viral CAP (positive viral swabs) by country. Countries are listed according to the number of patients enrolled.
Country Viral swab testing (1) Viral CAP (2) p-Value (1) p-Value (2)
Within the country,
n/N (%)
Other participating countries,
n/N (%)
Within the country,
n/N (%)
Other participating countries,
n/N (%)
Spain 164/643 (25.5) 389/3059 (12.7) 52/164 (31.7) 105/389 (27.0) 0.000 0.261
USA 81/477 (17.0) 472/3225 (14.6) 15/81 (18.5) 142/472 (30.1) 0.180 0.033
Italy 60/459 (13.1) 493/3243 (15.2) 26/60 (43.3) 131/493 (26.6) 0.231 0.007
Argentina 10/190 (5.3) 543/3512 (15.5) 0/10 (0.0) 157/543 (28.9) 0.000 0.044
UK 12/186 (6.5) 541/3516 (15.4) 2/12 (16.7) 155/541 (28.7) 0.001 0.362
Germany 20/173 (11.6) 533/3529 (15.1) 2/20 (10.0) 155/533 (29.1) 0.202 0.063
India 36/155 (23.2) 517/3547 (14.6) 19/36 (52.8) 138/517 (26.7) 0.003 0.001
Portugal 0/134 (0.0) 553/3568 (15.5) 0/0 (0.0) 157/553 (28.4) 0.000 1.000
Pakistan 1/109 (0.9) 552/3593 (15.4) 0/1 (0.0) 157/552 (28.4) 0.000 0.529
Croatia 1/103 (1.0) 552/3599 (15.3) 0/1 (0.0) 157/552 (28.4) 0.000 0.529
Denmark 20/89 (22.5) 533/3613 (14.8) 4/20 (20.0) 153/533 (28.7) 0.044 0.397
Greece 2/87 (2.3) 551/3615 (15.2) 1/2 (50.0) 156/551 (28.3) 0.001 0.497
France 17/66 (25.8) 536/3636 (14.7) 5/17 (29.4) 152/536 (28.4) 0.013 0.924
Serbia 0/56 (0.0) 553/3646 (15.2) 0/0 (0.0) 157/553 (28.4) 0.002 1.000
Bulgaria 0/51 (0.0) 553/3651 (15.1) 0/0 (0.0) 157/553 (28.4) 0.003 1.000
Montenegro 0/49 (0.0) 553/3653 (15.1) 0/0 (0.0) 157/553 (28.4) 0.003 1.000
Ireland 10/47 (21.3) 543/3655 (14.9) 0/10 (0.0) 157/543 (28.9) 0.220 0.044
Moldova 3/47 (6.4) 550/3655 (15.0) 1/3 (33.3) 156/550 (28.4) 0.098 0.849
Netherlands 33/46 (71.7) 520/3656 (14.2) 13/33 (39.4) 144/520 (27.7) 0.000 0.148
Saudi Arabia 28/43 (65.1) 525/3659 (14.3) 8/28 (28.6) 149/525 (28.4) 0.000 0.983
Egypt 2/38 (5.3) 551/3664 (15.0) 1/2 (50.0) 156/551 (28.3) 0.093 0.497
Mexico 2/38 (5.3) 551/3664 (15.0) 0/2 (0.0) 157/551 (28.5) 0.093 0.372
Belgium 9/35 (25.7) 544/3667 (14.8) 1/9 (11.1) 156/544 (28.7) 0.072 0.246
Turkey 8/33 (24.2) 545/3669 (14.9) 1/8 (12.5) 156/545 (28.6) 0.132 0.315
Colombia 15/27 (55.6) 538/3675 (14.6) 2/15 (13.3) 155/538 (28.8) 0.000 0.190
Israel 3/27 (11.1) 550/3675 (15.0) 1/3 (33.3) 156/550 (28.4) 0.576 0.849
Nigeria 0/27 (0.0) 553/3675 (15.0) 0/0 (0.0) 157/553 (28.4) 0.029 1.000
Australia 4/26 (15.4) 549/3676 (14.9) 2/4 (50.0) 155/549 (28.2) 0.949 0.336
Romania 0/20 (0.0) 553/3682 (15.0) 0/0 (0.0) 157/553 (28.4) 0.060 1.000
Lebanon 0/19 (0.0) 553/3683 (15.0) 0/0 (0.0) 157/553 (28.4) 0.067 1.000
(continued on next page)
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Table A2 (continued)
Country Viral swab testing (1) Viral CAP (2) p-Value (1) p-Value (2)
Within the country,
n/N (%)
Other participating countries,
n/N (%)
Within the country,
n/N (%)
Other participating countries,
n/N (%)
Japan 0/17 (0.0) 553/3685 (15.0) 0/0 (0.0) 157/553 (28.4) 0.083 1.000
Nepal 0/17 (0.0) 553/3685 (15.0) 0/0 (0.0) 157/553 (28.4) 0.083 1.000
New Zealand 0/14 (0.0) 553/3688 (15.0) 0/0 (0.0) 157/553 (28.4) 0.116 1.000
Panama 0/14 (0.0) 553/3688 (15.0) 0/0 (0.0) 157/553 (28.4) 0.116 1.000
South Africa 0/13 (0.0) 553/3689 (15.0) 0/0 (0.0) 157/553 (28.4) 0.130 1.000
United Arab Emirates 8/13 (61.5) 545/3689 (14.8) 1/8 (12.5) 156/545 (28.6) 0.000 0.315
Zambia 0/13 (0.0) 553/3689 (15.0) 0/0 (0.0) 157/553 (28.4) 0.130 1.000
Benin 0/12 (0.0) 553/3690 (15.0) 0/0 (0.0) 157/553 (28.4) 0.146 1.000
Ghana 0/12 (0.0) 553/3690 (15.0) 0/0 (0.0) 157/553 (28.4) 0.146 1.000
Ethiopia 0/10 (0.0) 553/3692 (15.0) 0/0 (0.0) 157/553 (28.4) 0.185 1.000
Togo 0/9 (0.0) 553/3693 (15.0) 0/0 (0.0) 157/553 (28.4) 0.208 1.000
Cameroon 0/8 (0.0) 553/3694 (15.0) 0/0 (0.0) 157/553 (28.4) 0.235 1.000
Tunisia 0/7 (0.0) 553/3695 (15.0) 0/0 (0.0) 157/553 (28.4) 0.267 1.000
China 2/6 (33.3) 551/3696 (14.9) 0/2 (0.0) 157/551 (28.5) 0.206 0.372
Russia 0/6 (0.0) 553/3696 (15.0) 0/0 (0.0) 157/553 (28.4) 0.304 1.000
Austria 2/5 (40.0) 551/3697 (14.9) 0/2 (0.0) 157/551 (28.5) 0.116 0.372
Ukraine 0/5 (0.0) 553/3697 (15.0) 0/0 (0.0) 157/553 (28.4) 0.348 1.000
Iran 0/4 (0.0) 553/3698 (15.0) 0/0 (0.0) 157/553 (28.4) 0.402 1.000
Poland 0/4 (0.0) 553/3698 (15.0) 0/0 (0.0) 157/553 (28.4) 0.402 1.000
Gambia 0/4 (0.0) 553/3698 (15.0) 0/0 (0.0) 157/553 (28.4) 0.402 1.000
Bahrain 0/3 (0.0) 553/3699 (14.9) 0/0 (0.0) 157/553 (28.4) 0.468 1.000
Congo 0/3 (0.0) 553/3699 (14.9) 0/0 (0.0) 157/553 (28.4) 0.468 1.000
South Korea 0/2 (0.0) 553/3700 (14.9) 0/0 (0.0) 157/553 (28.4) 0.553 1.000
Brazil 0/1 (0.0) 553/3701 (14.9) 0/0 (0.0) 157/553 (28.4) 0.675 1.000
Statistically significant frequencies compared with other continents/countries are in bold.
Table A3
Bacterial and fungal coinfections in patients with viral CAP.
Pathogen None S.
aureus
S. pneumo-
niae
Aspergillus
spp.
H. influ-
enzae
E. fae-
calis
coagulase neg.
Staphilococci
Nocardia
spp.
Actinomices Mixed anaerobic
bacteria
Adenovirus RSV Total
Adenovirus 3 / / / / / / / / / / / 3
Corona virus 6 / / / / / / / / / / / 6
Influenza virus 110 4 3 2 2 1 1 1 1 / 1 1 127
Metapneumovirus 4 / / / / / / / / / / / 4
RSV 7 / 1 / / / / / / 1 / / 9
Rhinovirus/Enter-
ovirus
6 1 / / 1 / / / / / / / 8
RSV= Respiratory Syncytial virus; spp.= species.
Table A4
Independent risk factors for viral CAP in multivariate logistic regression analysis among all the patients who underwent at least one viral swab and had a concomitant
virus isolated.
OR (95% IC) p-Value
Obesity 1.59 (1.01–2.48) 0.043
LTOT 0.74 (0.26–2.16) 0.582
ICS use 0.68 (0.38–1.24) 0.207
Influenza vaccine 0.79 (0.47–1.33) 0.377
PPSV23 0.59 (0.28–1.21) 0.148
Age (categorized) 0.90 (0.61–1.35) 0.623
Bronchiectasis 0.53 (0.14–1.93) 0.334
ILD 0 0.988
Hospitalization in previous 12months 0.81 (0.51–1.30) 0.385
Need for invasive mechanical ventilation 1.62 (1.02–2.56) 0.040
LTOT = long term oxygen therapy; ICS = inhaled corticosteroids; PPSV23 = pneumococcal polysaccharide vaccine 23-valent; ILD = interstitial lung disease; OR = odds ratio
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Table A5
Frequency of oseltamivir empirical coverage by continent and by country.
Continent Within the continent n/N (%) Other continents n/N (%) p-Value
North America 9/529 (1.7) 179/3173 (5.6) <0.001
South America 15/218 (6.9) 13/3484 (5.0) 0.212
Africa 0/156 (0.0) 188/3546 (5.3) 0.003
Asia 63/415 (15.2) 125/3287 (3.8) <0.001
Europe 99/2344 (4.2) 89/1358 (6.6) 0.002
Oceania 2/40 (5.0) 186/3662 (5.1) 0.982
Country Within the country n/N (%) Other participating
countries n/N (%)
p-Value
Spain 46/643(7.2) 142/3059 (4.6) 0.008
USA 7/477 (1.5) 181/3225 (5.6) <0.001
Italy 24/459 (5.2) 164/3/3243 (5.1) 0.875
Argentina 10/190 (5.3) 178/3512 (5.1) 0.905
UK 3/186 (1.6) 158/3516 (5.3) 0.027
Germany 0/173 (0.0) 188/3529 (5.3) 0.002
India 41/155 (26.5) 147/3547 (4.1) <0.001
Portugal 0/134 (0.0) 188/3568 (5.3) 0.006
Pakistan 0/109 (0.0) 188/3593 (5.2) 0.014
Croatia 0/103 (0.0) 188/3599 (5.2) 0.017
Denmark 1/89 (1.1) 187/3613 (5.2) 0.085
Greece 11/87 (12.6) 177/3615 (4.9) 0.001
France 6/66 (9.1) 182/3636 (5.0) 0.134
Serbia 1/56 (1.8) 187/3646 (5.1) 0.258
Bulgaria 2/51 (3.9) 186/3651 (5.1) 0.705
Montenegro 0/49 (0.0) 188/3653 (5.1) 0.103
Ireland 0/47 (0.0) 188/3655 (5.1) 0.111
Moldova 1/47 (2.1) 187/3655 (5.1) 0.354
Netherlands 0/46 (0.0) 188/3656 (5.1) 0.114
Saudi Arabia 14/43 (32.6) 174/3659 (4.8) <0.001
Egypt 0/38 (0.0) 188/3664 (5.1) 0.152
Mexico 2/38 (5.3) 186/3664 (5.1) 0.958
Belgium 1/35 (2.9) 187/3667 (5.1) 0.548
Turkey 2/33 (6.1) 186/3669 (5.1) 0.796
Colombia 5/27 (18.5) 183/3675 (5.0) 0.001
Israel 0/27 (0.0) 188/3675 (5.1) 0.228
Nigeria 0/27 (0.0) 188/3675 (5.1) 0.228
Australia 2/26 (7.7) 186/3676 (5.1) 0.542
Romania 0/20 (0.0) 188/3682 (5.1) 0.300
Lebanon 0/19 (0.0) 188/3683 (5.1) 0.312
Japan 0/17 (0.0) 188/3685 (5.1) 0.339
Nepal 0/17 (0.0) 188/3685 (5.1) 0.339
New Zealand 0/14 (0.0) 188/3688 (5.1) 0.386
Panama 0/14 (0.0) 188/3688 (5.1) 0.386
South Africa 0/13 (0.0) 188/3689 (5.1) 0.403
United Arab Emirates 8/13 (61.5) 180/3689 (4.9) <0.001
Zambia 0/13 (0.0) 188/3689 (5.1) 0.403
Benin 0/12 (0.0) 188/3690 (5.1) 0.422
Ghana 0/12 (0.0) 188/3690 (5.1) 0.422
Ethiopia 0/10 (0.0) 188/3692 (5.1) 0.464
Togo 0/9 (0.0) 188/3693 (5.1) 0.487
Cameroon 0/8 (0.0) 188/3694 (5.1) 0.513
Tunisia 0/7 (0.0) 188/3695 (5.1) 0.540
China 0/6 (0.0) 188/3696 (5.1) 0.571
Russia 0/6 (0.0) 188/3696 (5.1) 0.571
Austria 1/5 (20.0) 187/3697 (5.1) 0.128
Ukraine 0/5 (0.0) 188/3697 (5.1) 0.605
Iran 0/4 (0.0) 188/3698 (5.1) 0.643
Poland 0/4 (0.0) 188/3698 (5.1) 0.643
Gambia 0/4 (0.0) 188/3698 (5.1) 0.643
Bahrain 0/3 (0.0) 188/3699 (5.1) 0.689
Congo 0/3 (0.0) 188/3699 (5.1) 0.689
South Korea 0/2 (0.0) 188/3700 (5.1) 0.744
Brazil 0/1 (0.0) 188/3701 (5.1) 0.817
Statistically significant frequencies compared with other continents/countries are in bold.
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